Kartik Konduri
Baylor University Medical Center
8 Papers
5 Citations
Kartik Konduri is an academic researcher from Baylor University Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 4 publications. Previous affiliations of Kartik Konduri include Texas Oncology.
Chat about Author
Papers
EGFR fusions as novel therapeutic targets in lung cancer
Kartik Konduri,Jean-Nicolas Gallant,Young Kwang Chae,Francis J. Giles,Barbara J. Gitlitz,Kyle Gowen,Eiki Ichihara,Taofeek K. Owonikoko,Vijay Peddareddigari,Suresh S. Ramalingam,Satyanarayan K. Reddy,Beth Eaby-Sandy,Tiziana Vavalà,Andrew Whiteley,Heidi Chen,Yingjun Yan,Jonathan H. Sheehan,Jens Meiler,Deborah Morosini,Jeffrey S. Ross,Philip J. Stephens,Vincent A. Miller,Siraj M. Ali,Christine M. Lovly +23 more
TL;DR: The identification and therapeutic targeting of EGFR C-terminal fusions in patients with lung cancer are reported and responses to the EGFR inhibitor erlotinib are documented in 4 patients whose tumors harbored EGFR fusions.
119
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
Sara D. Robinson,Joyce O'Shaughnessy,Joyce O'Shaughnessy,C. Lance Cowey,C. Lance Cowey,Kartik Konduri,Kartik Konduri +6 more
TL;DR: The regression of intracranial disease indicated vemurafenib was able to cross the blood-brain barrier and was efficacious in treating brain metastases in this patient with lung cancer.
99
Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors.
Garrett M. Frampton,Siraj M. Ali,Margaret Rosenzweig,Jonathan W. Goldman,Carrie B. Lee,Jared Weiss,Jose A. Bufill,Ravi Salgia,Mohammad Jahanzeb,Kartik Konduri,Patrick M. Forde,Deborah Morosini,Jeffrey S. Ross,Sai-Hong Ignatius Ou,Roman Yelensky,Vincent A. Miller,Philip J. Stephens +16 more
TL;DR: Comprehensive genomic profiling of a large series of advanced cancers identified 200 cases harboring METex14 alterations, which cause exon skipping, MET activation, and predict sensitivity to MET inhibitors in vitro.
5
Abstract CT229: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors
Tejas Patil,Daniel R. Carrizosa,Mark E. Burkard,Karen L. Reckamp,Jayesh Desai,Young Kwang Chae,Stephen V. Liu,Kartik Konduri,Shirish M. Gadgeel,Jessica Lin,Parneet Cheema,David Spiegel,Alison M. Schram,Valerie M. Jansen,Yasir Elamin +14 more
TL;DR: Seribantumab is a fully human anti-HER3 IgG2 monoclonal antibody that blocks aberrant NRG1 fusion protein binding to HER3 thereby preventing ligand-dependent activation and dimerization resulting in complete inhibition of the PI3K/AKT and MAPK downstream signaling pathways as discussed by the authors .
4